Poseida Therapeutics (NASDAQ:PSTX) Given Buy Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Poseida Therapeutics (NASDAQ:PSTX) in a research report sent to investors on Friday,Benzinga reports. HC Wainwright currently has a $20.00 price target on the stock.

Poseida Therapeutics Stock Down 14.0 %

Shares of PSTX traded down $0.45 during mid-day trading on Friday, hitting $2.76. 702,037 shares of the company’s stock were exchanged, compared to its average volume of 564,758. The stock’s 50-day moving average is $2.81 and its 200-day moving average is $2.92. The company has a debt-to-equity ratio of 0.68, a quick ratio of 3.20 and a current ratio of 3.20. Poseida Therapeutics has a fifty-two week low of $1.87 and a fifty-two week high of $4.27. The company has a market cap of $268.99 million, a price-to-earnings ratio of -4.38 and a beta of 0.54.

Institutional Investors Weigh In On Poseida Therapeutics

Several large investors have recently bought and sold shares of the stock. Blair William & Co. IL raised its holdings in Poseida Therapeutics by 41.3% in the first quarter. Blair William & Co. IL now owns 965,052 shares of the company’s stock valued at $3,079,000 after acquiring an additional 282,310 shares in the last quarter. Renaissance Technologies LLC lifted its stake in Poseida Therapeutics by 53.4% during the second quarter. Renaissance Technologies LLC now owns 854,900 shares of the company’s stock worth $2,496,000 after purchasing an additional 297,500 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Poseida Therapeutics by 16.3% in the 1st quarter. Vanguard Group Inc. now owns 3,373,065 shares of the company’s stock valued at $10,760,000 after buying an additional 473,746 shares in the last quarter. Public Employees Retirement System of Ohio lifted its holdings in shares of Poseida Therapeutics by 177.3% in the 1st quarter. Public Employees Retirement System of Ohio now owns 62,945 shares of the company’s stock valued at $201,000 after purchasing an additional 40,245 shares during the last quarter. Finally, Lazard Asset Management LLC lifted its stake in Poseida Therapeutics by 280.3% in the first quarter. Lazard Asset Management LLC now owns 28,679 shares of the company’s stock valued at $91,000 after buying an additional 21,138 shares during the last quarter. Hedge funds and other institutional investors own 46.87% of the company’s stock.

Poseida Therapeutics Company Profile

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.